Kong’s Pharmaceutical Co. has divulged Ras-related C3 botulinum toxin substrate 1 (RAC1; TC25) inhibitors reported to be useful for the treatment of cancer and neurologic disorders.
Chinese University of Hong Kong has identified peptides acting as serine/arginine-rich protein-specific kinase 1 (SRSF protein kinase 1; SRPK1) inhibitors reported to be useful for the treatment of lung cancer, breast cancer, coronavirus acute respiratory syndrome, hepatitis and herpes viral infections.
Modex Therapeutics Inc. has developed MDX-2003, a first-in-class tetraspecific T-cell engager targeting CD19 and CD20 on B cells, while co-engaging CD3 and CD28 on T cells.
Approaches that recruit and activate tumor-infiltrating T cells could help reshape the immunosuppressive tumor microenvironment, making immunotherapy more effective for patients with microsatellite stability and low microsatellite instability colorectal cancers. Oncolytic viruses can offer an alternative to help stimulate the antitumor immunity in ‘cold’ tumors.
Monte Rosa Therapeutics Inc. plans a signal-verifying phase II trial next year after making known the positive interim data from an ongoing phase I/II trial testing molecular glue degrader MRT-2359 in combination with androgen receptor (AR) inhibitor Xtandi (enzalutamide, Astellas Pharma Inc.). The investigation targeted heavily pretreated patients with metastatic castration-resistant prostate cancer bearing AR mutations.
Hangzhou Baicreat Pharma-Tech Co. Ltd. has identified tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer.
Genome Therapeutics Ltd. has disclosed compounds and their immunoconjugates comprising an antibody covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Sumitomo Pharma Co. Ltd. is developing the Menin (MEN1)-myeloid/lymphoid or mixed-lineage leukemia (MLL) interaction inhibitor DSP-5336 (enzomenib) for the treatment of MLL-rearranged acute myeloid leukemia.
RSS
